Cargando…

Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review

Sickle cell disease (SCD) is a group of inherited red blood cell disorders affecting millions worldwide. The median life expectancy of someone with SCD remains significantly low despite improvements in standards of care and the implementation of hydroxyurea therapy. Notably, a 20-year interval exist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dick, Maurice H, Abdelgadir, Arowa, Kulkarni, Vaishnavi Vijaya, Akram, Hamna, Chatterjee, Abanti, Pokhrel, Sushil, Khan, Safeera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Family/General Practice
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187358/ https://www.ncbi.nlm.nih.gov/pubmed/35706735 http://dx.doi.org/10.7759/cureus.24920

Ejemplares similares

Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review
por: Ahmed, Nabeel R, et al.
Publicado: (2022)

A Better Understanding of Moyamoya in Trisomy 21: A Systematic Review
por: Abdelgadir, Arowa, et al.
Publicado: (2022)

Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
por: Migotsky, Michael, et al.
Publicado: (2022)

More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
por: Langley, Paul C
Publicado: (2020)

5610357 REDUCTION IN BLOOD TRANSFUSION BURDEN FOLLOWING INITIATION OF VOXELOTOR OR CRIZANLIZUMAB: A CASE SERIES
por: Baruwa Etti, A., et al.
Publicado: (2023)

P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab
por: Karki, Nabin Raj, et al.
Publicado: (2021)

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
por: Delgado, Julio, et al.
Publicado: (2021)

PB2213: EFFECTIVENESS OF CRIZANLIZUMAB IN REDUCING VASO-OCCLUSIVE CRISIS IN PATIENTS WITH SICKLE CELL DISEASE IN BRAZIL: STUDY PROTOCOL FOR AN OBSERVATIONAL, RETROSPECTIVE, MULTICENTER, NATIONAL STUDY
por: Bueno, C., et al.
Publicado: (2022)

Voxelotor: A Ray of Hope for Sickle Disease
por: AlDallal, Salma M
Publicado: (2020)

Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report
por: Alshurafa, Awni, et al.
Publicado: (2022)

Patient perception of voxelotor treatment benefit in sickle cell disease
por: Idowu, Modupe, et al.
Publicado: (2022)

Practical Guidance for the Use of Voxelotor in the Management of Sickle Cell Disease
por: Barriteau, Christina M, et al.
Publicado: (2022)

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease
por: Kanter, Julie, et al.
Publicado: (2022)

The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease
por: Minniti, Caterina P., et al.
Publicado: (2021)

Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
por: Yenamandra, Avani, et al.
Publicado: (2020)

P1450: VOXELOTOR TREATMENT LEADS TO IMPROVED VIABILITY OF SICKLE ERYTHROCYTES
por: Konté, Kadère, et al.
Publicado: (2023)

UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
por: Buka, Richard J, et al.
Publicado: (2022)

Comparative study of hypercoagulability change in steady state and during vaso-occlusive crisis among Sudanese patients living with sickle cell disease
por: Mohamed, Elmigdad Abdelgadir, et al.
Publicado: (2020)

Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease
por: Telfer, Paul, et al.
Publicado: (2018)

Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe
por: Ferlis, Mica, et al.
Publicado: (2022)

Modeling the public health impact of voxelotor in the management of sickle cell disease in France
por: Galacteros, Frédéric, et al.
Publicado: (2023)

Real-World Data of Crizanlizumab in Sickle Cell Disease: A Single-Center Analysis
por: Cheplowitz, Halle, et al.
Publicado: (2023)

Sickle cell vaso-occlusive crisis: it’s a gut feeling
por: Lim, Seah H., et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease
por: Hutchaleelaha, Athiwat, et al.
Publicado: (2019)

Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor
por: Glaros, Alexander K., et al.
Publicado: (2021)

S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP)
por: Silva-Pinto, A, et al.
Publicado: (2022)

Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date
por: Riley, Tanya R, et al.
Publicado: (2019)

Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis
por: Thom, Howard, et al.
Publicado: (2020)

The Role of Infection in the Pathogenesis of Vaso-Occlusive Crisis in Patients with Sickle Cell Disease.
por: Ahmed, Sagir G.
Publicado: (2011)

Defective lipid metabolism in sickle cell anaemia subjects in vaso-occlusive crisis
por: Akinlade, Kehinde Sola, et al.
Publicado: (2014)

Procalcitonin as a Biomarker of Bacterial Infection in Sickle Cell Vaso-Occlusive Crisis
por: Patel, Dilip Kumar, et al.
Publicado: (2014)

Pancreatitis in the Setting of Vaso-occlusive Sickle Cell Crisis: A Rare Encounter
por: Hasan, Badar, et al.
Publicado: (2017)

Vaso-occlusive crisis in sickle cell disease: current paradigm on pain management
por: Uwaezuoke, Samuel N, et al.
Publicado: (2018)

Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease
por: Osunkwo, Ifeyinwa, et al.
Publicado: (2020)

Sickle Cell Disease: Metabolomic Profiles of Vaso-Occlusive Crisis in Plasma and Erythrocytes
por: Dembélé, Klétigui Casimir, et al.
Publicado: (2020)

Effect of Weather on Frequency of Vaso-Occlusive Crisis in Children With Sickle Cell Disease
por: Almuqamam, Mohamed, et al.
Publicado: (2021)

Vaso‐occlusive crisis in a patient with sickle cell trait and COVID‐19
por: Freitas, Luiz A. R., et al.
Publicado: (2021)

Letter to the Editor: Role of Ketamine in Vaso-Occlusive Crisis of Sickle Cell Disease
por: Raghuraman, M. S.
Publicado: (2022)

P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
por: Silva-Pinto, A. C., et al.
Publicado: (2022)

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS
por: Abboud, Miguel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qeieauu586tsk0k9bb769k3psn